CDI In the News

October 04, 2021

Tokyo, September 30, 2021 — FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) has reached agreement on core terms with Australian regenerative medicine venture Cynata Therapeutics Limited (Cynata) to manufacture regenerative medicine products using induced pluripotent stem (iPS) cells. Based on the core terms, Fujifilm will conduct clinical and commercial manufacturing for Cynata’s pipeline….

May 17, 2021

Cambridge, Mass., and Madison, Wis. [May 17, 2021] – BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D.,….

March 17, 2021

FUJIFILM Cellular Dynamics, Inc. and Sana Biotechnology, Inc. announced today that Sana has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development of commercial cell therapies.

November 30, 2020

Cell & Gene Therapy Insights 2020; 6(10), 1507–1512